Thursday 16 May 2013

Pathological response and survival after neoadjuvant therapy for breast cancer

Pathological response and survival after neoadjuvant therapy for breast cancer: A 30-year study. The breast, June 2013, Vol. 22(3), p.301-08

Guiu, S., et al.

http://www.thebreastonline.com/article/PIIS0960977612001634/abstract?rss=yes

HER2-positive and triple-negative breast cancer (TNBC) still have a poor prognosis. Pathological complete response (pCR) is usually considered a surrogate marker for outcome. The aim of this study was to reconsider these parameters on a large population after a long follow-up.